259 related articles for article (PubMed ID: 34385976)
1. Circulating Ceramides- Are Origins Important for Sphingolipid Biomarkers and Treatments?
Mah M; Febbraio M; Turpin-Nolan S
Front Endocrinol (Lausanne); 2021; 12():684448. PubMed ID: 34385976
[TBL] [Abstract][Full Text] [Related]
2. Circulating Sphingolipids in Insulin Resistance, Diabetes and Associated Complications.
Hammad SM; Lopes-Virella MF
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762318
[TBL] [Abstract][Full Text] [Related]
3. Ceramides and Ceramide Scores: Clinical Applications for Cardiometabolic Risk Stratification.
Hilvo M; Vasile VC; Donato LJ; Hurme R; Laaksonen R
Front Endocrinol (Lausanne); 2020; 11():570628. PubMed ID: 33133018
[TBL] [Abstract][Full Text] [Related]
4. Circulating Sphingolipids, Insulin, HOMA-IR, and HOMA-B: The Strong Heart Family Study.
Lemaitre RN; Yu C; Hoofnagle A; Hari N; Jensen PN; Fretts AM; Umans JG; Howard BV; Sitlani CM; Siscovick DS; King IB; Sotoodehnia N; McKnight B
Diabetes; 2018 Aug; 67(8):1663-1672. PubMed ID: 29588286
[TBL] [Abstract][Full Text] [Related]
5. Sphingolipids and Lipoproteins in Health and Metabolic Disorders.
Iqbal J; Walsh MT; Hammad SM; Hussain MM
Trends Endocrinol Metab; 2017 Jul; 28(7):506-518. PubMed ID: 28462811
[TBL] [Abstract][Full Text] [Related]
6. Short communication: Circulating fatty acylcarnitines are elevated in overweight periparturient dairy cows in association with sphingolipid biomarkers of insulin resistance.
Rico JE; Zang Y; Haughey NJ; Rius AG; McFadden JW
J Dairy Sci; 2018 Jan; 101(1):812-819. PubMed ID: 29103713
[TBL] [Abstract][Full Text] [Related]
7. Circulating sphingolipids, fasting glucose, and impaired fasting glucose: The Strong Heart Family Study.
Jensen PN; Fretts AM; Yu C; Hoofnagle AN; Umans JG; Howard BV; Sitlani CM; Siscovick DS; King IB; Sotoodehnia N; McKnight B; Lemaitre RN
EBioMedicine; 2019 Mar; 41():44-49. PubMed ID: 30594552
[TBL] [Abstract][Full Text] [Related]
8. Plasma cross-gestational sphingolipidomic analyses reveal potential first trimester biomarkers of preeclampsia.
Dobierzewska A; Soman S; Illanes SE; Morris AJ
PLoS One; 2017; 12(4):e0175118. PubMed ID: 28384202
[TBL] [Abstract][Full Text] [Related]
9. Serum lipidomics reveals early differential effects of gastric bypass compared with banding on phospholipids and sphingolipids independent of differences in weight loss.
Kayser BD; Lhomme M; Dao MC; Ichou F; Bouillot JL; Prifti E; Kontush A; Chevallier JM; Aron-Wisnewsky J; Dugail I; Clément K
Int J Obes (Lond); 2017 Jun; 41(6):917-925. PubMed ID: 28280270
[TBL] [Abstract][Full Text] [Related]
10. Circulating sphingolipid biomarkers in models of type 1 diabetes.
Fox TE; Bewley MC; Unrath KA; Pedersen MM; Anderson RE; Jung DY; Jefferson LS; Kim JK; Bronson SK; Flanagan JM; Kester M
J Lipid Res; 2011 Mar; 52(3):509-17. PubMed ID: 21068007
[TBL] [Abstract][Full Text] [Related]
11. Ceramides and other sphingolipids as drivers of cardiovascular disease.
Choi RH; Tatum SM; Symons JD; Summers SA; Holland WL
Nat Rev Cardiol; 2021 Oct; 18(10):701-711. PubMed ID: 33772258
[TBL] [Abstract][Full Text] [Related]
12. Ceramide Biomarkers Predictive of Cardiovascular Disease Risk Increase in Healthy Older Adults After Bed Rest.
Petrocelli JJ; McKenzie AI; Mahmassani ZS; Reidy PT; Stoddard GJ; Poss AM; Holland WL; Summers SA; Drummond MJ
J Gerontol A Biol Sci Med Sci; 2020 Sep; 75(9):1663-1670. PubMed ID: 32215553
[TBL] [Abstract][Full Text] [Related]
13. Plasma sphingolipids and risk of cardiovascular diseases: a large-scale lipidomic analysis.
Seah JYH; Chew WS; Torta F; Khoo CM; Wenk MR; Herr DR; Choi H; Tai ES; van Dam RM
Metabolomics; 2020 Aug; 16(9):89. PubMed ID: 32816082
[TBL] [Abstract][Full Text] [Related]
14. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.
Holland WL; Summers SA
Endocr Rev; 2008 Jun; 29(4):381-402. PubMed ID: 18451260
[TBL] [Abstract][Full Text] [Related]
15. Serum sphingolipids: relationships to insulin sensitivity and changes with exercise in humans.
Bergman BC; Brozinick JT; Strauss A; Bacon S; Kerege A; Bui HH; Sanders P; Siddall P; Kuo MS; Perreault L
Am J Physiol Endocrinol Metab; 2015 Aug; 309(4):E398-408. PubMed ID: 26126684
[TBL] [Abstract][Full Text] [Related]
16. Sphingolipid metabolism in non-alcoholic fatty liver diseases.
Régnier M; Polizzi A; Guillou H; Loiseau N
Biochimie; 2019 Apr; 159():9-22. PubMed ID: 30071259
[TBL] [Abstract][Full Text] [Related]
17. Sphingolipids and microRNA Changes in Blood following Blast Traumatic Brain Injury: An Exploratory Study.
Sajja VSSS; Jablonska A; Haughey N; Bulte JWM; Stevens RD; Long JB; Walczak P; Janowski M
J Neurotrauma; 2018 Jan; 35(2):353-361. PubMed ID: 29020847
[TBL] [Abstract][Full Text] [Related]
18. Ceramide Metabolism in Cardiovascular Disease: A Network With High Therapeutic Potential.
Zietzer A; Düsing P; Reese L; Nickenig G; Jansen F
Arterioscler Thromb Vasc Biol; 2022 Oct; 42(10):1220-1228. PubMed ID: 36004640
[TBL] [Abstract][Full Text] [Related]
19. Bioactive Sphingolipids as Biomarkers Predictive of Disease Severity and Treatment Response in Cancer: Current Status and Translational Challenges.
Sedić M; Grbčić P; Pavelić SK
Anticancer Res; 2019 Jan; 39(1):41-56. PubMed ID: 30591439
[TBL] [Abstract][Full Text] [Related]
20. Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome?
Othman A; Rütti MF; Ernst D; Saely CH; Rein P; Drexel H; Porretta-Serapiglia C; Lauria G; Bianchi R; von Eckardstein A; Hornemann T
Diabetologia; 2012 Feb; 55(2):421-31. PubMed ID: 22124606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
